Skip to main content

Table 1 Clinical and pathological characteristic of the breast cancer patients

From: Hypermethylated 14-3-3-σ and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis

Characteristics Disease-Free Breast Cancer Group Metastatic Breast Cancer Group
Histological type   
Invasive ductal carcinoma 63 (81.8%) 22 (64.7%)
Invasive lobular carcinoma 8 (10.4%) 6 (17.6%)
Other invasive carcinoma 6 (7.8%) 4 (11.4%)
Unknown 0 2 (5.8%)
Histological grade   
Grade I 17 (22.1%) 1 (2.9%)
Grade II 25 (32.5%) 8 (23.5%)
Grade III 26 (33.8%) 20 (58.8%)
Unknown 9 (11.7%) 5 (14.7%)
Tumor size   
Tis 2 (2.6%) 1 (2.9%)
T1 40 (52.0%) 10 (29.4%)
T2 24 (31.2%) 13 (38.2%)
T3 7 (9.1%) 5 (14.7%)
T4 4 (5.2%) 2 (5.8%)
Tx 0 1 (2.9%)
Unknown   2 (5.8%)
Node involvement   
N0 41 (53.3%) 13 (38.2%)
N1 26 (33.8%) 8 (23.5%)
N2 6 (7.8%) 9 (26.4%)
N3 3 (3.9%) 2 (5.8%)
Nx 1 (1.3%) 2 (5.8%)
Estrogen receptor status   
Negative 20 (25.1%) 10 (27.7%)
Positive 53 (68.8%) 21 (61.7%)
Unknown 4 (5.2%) 3 (8.8%)
Progesterone receptor status   
Negative 23 (30.0%) 10 (29.4%)
Positive 50 (64.9%) 22 (64.7%)
Unknown 4 (5.1%) 2 (5.8%)
Menopause   
Yes 46 (62.3%) 31 (91.1%)
No 26 (33.8%)  
Unknown 3 (3.9%) 3 (8.8%)